Jun 2026 (Q2 FY26) — Aug 4, 2026
PROCEPT BioRobotics Q2 FY26 — HYDROS Strength Amidst Legacy AQUABEAM Softness
Read the full callPROCEPT BioRobotics (PRCT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
PROCEPT BioRobotics earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 94.5 | +19.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -29.0 | −1.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -26.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$18.15 +3.66% · +$0.64
Performance −46.5% 1Y
1Y: $33.92 on 14 Oct 2025 → $18.15. High $36.95 (28 Oct 2025), low $16.69 (24 Jul 2026).
- Previous close
- $17.51
- 52-week range
- $16.69 – $36.95
- One year
- −46.24%
Overview
- Symbol
- PRCT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
PROCEPT BioRobotics earnings calls (PRCT)
Financials
What the filings say
Net profit, year on year: −37% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 58 | 68 | 69 | 79 | 83 | 76 | 83 | 94 |
| Operating profit | -22 | -20 | -27 | -22 | -23 | -31 | -33 | -27 |
| Operating margin | −38.4% | −28.9% | −39.7% | −28.0% | −27.8% | −40.6% | −39.2% | −29.0% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | — | — | -25 | -19 | — | — | -32 | -27 |
| Tax rate | — | — | 0.2% | −0.7% | — | — | 0.1% | −0.3% |
| Net profit | -21 | -19 | -25 | -20 | -21 | -30 | -32 | -27 |
| EPS ($ per share) | -0.40 | — | -0.45 | -0.35 | -0.38 | — | -0.56 | -0.47 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -202 | -262 | -349 | -455 | -546 | -642 |
| Total liabilities | 65 | 70 | 112 | 124 | 132 | 142 |
| Fixed assets | 8 | 5 | 9 | 29 | 27 | 30 |
| Total assets | 126 | 337 | 309 | 405 | 534 | 508 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -48 | -57 | -80 | -108 | -99 | -49 |
| Cash from investing | -0 | -1 | -3 | -25 | -4 | -9 |
| Cash from financing | 107 | 262 | 4 | 168 | 180 | 11 |
| Net cash flow | 58 | 204 | -79 | 35 | 77 | -47 |
| Capital expenditure | -0 | -1 | -3 | -25 | -4 | -9 |
| Free cash flow | -49 | -58 | -83 | -133 | -104 | -58 |
Insider filings
41 filings between Feb 19, 2026 and Oct 2, 2026.
Open market
decisions to buy or sellPurchases
$10.98M
8 purchases by 2 insiders
Sales
$623.8K
14 sales by 3 insiders
14% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 19
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Desai Antal Rohit | $10.48M | — | Mar 9, 2026 |
| Wood Larry L | $498.3K | — | Aug 7, 2026 |
| Nouri Alaleh | — | $408.7K | Sep 9, 2026 |
| Waters Kevin | — | $197.2K | Sep 9, 2026 |
| Templin Barry L | — | $18.0K | Sep 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Mack Michael Director | Award | 7,727 | $0 |
| Sep 9, 2026 | Waters Kevin EVP, CFO | Sale | 373 | $7.8K |
| Sep 9, 2026 | Templin Barry L EVP, Chief Technology Officer | Sale | 373 | $7.8K |
| Sep 9, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Sale | 297 | $6.2K |
| Aug 13, 2026 | Templin Barry L EVP, Chief Technology Officer | Award | 26,246 | $0 |
| Aug 13, 2026 | Waters Kevin EVP, CFO | Award | 29,527 | $0 |
| Aug 13, 2026 | Sharma Pooja Chief Strat/Marketing Officer | Award | 23,622 | $0 |
| Aug 13, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Award | 22,965 | $0 |
| Aug 7, 2026 | Wood Larry L President, CEO | Purchase | 23,900 | $498.3K |
| Jun 9, 2026 | Garrett Mary Director | Award | 3,315 | $0 |
| Jun 9, 2026 | Harris Taylor C. Director | Award | 3,315 | $0 |
| Jun 9, 2026 | Sandoval Elisabeth Director | Award | 3,315 | $0 |
| Jun 9, 2026 | MOLL FREDERIC H Director | Award | 3,315 | $0 |
| Jun 9, 2026 | Dodrill Amy M. Director | Award | 3,315 | $0 |
| Jun 9, 2026 | PRESCOTT THOMAS M Director | Award | 3,315 | $0 |
| Jun 9, 2026 | Desai Antal Rohit Director | Award | 3,315 | $0 |
| Jun 9, 2026 | PUCKETT DAN Director | Award | 3,315 | $0 |
| Jun 8, 2026 | Waters Kevin EVP, CFO | Sale | 357 | $10.2K |
| Jun 8, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Sale | 285 | $8.1K |
| Jun 8, 2026 | Templin Barry L EVP, Chief Technology Officer | Sale | 358 | $10.2K |
| Mar 19, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Sale 10b5-1 plan | 2,332 | $61.0K |
| Mar 19, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Sale 10b5-1 plan | 3,031 | $78.3K |
| Mar 17, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Sale | 304 | $8.6K |
| Mar 17, 2026 | Waters Kevin EVP, CFO | Sale | 706 | $19.9K |
| Mar 10, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Sale | 145 | $3.9K |
| Mar 10, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Sale | 3,098 | $79.3K |
| Mar 9, 2026 | Desai Antal Rohit Director | Purchase | 53,818 | $1.34M |
| Mar 9, 2026 | Desai Antal Rohit Director | Purchase | 1,300 | $33.0K |
| Mar 9, 2026 | Desai Antal Rohit Director | Purchase | 43,581 | $1.05M |
| Mar 6, 2026 | Desai Antal Rohit Director | Purchase | 53,763 | $1.30M |
| Mar 6, 2026 | Desai Antal Rohit Director | Purchase | 106,554 | $2.49M |
| Mar 6, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Sale | 6,892 | $163.4K |
| Mar 6, 2026 | Waters Kevin EVP, CFO | Sale | 6,721 | $159.3K |
| Mar 5, 2026 | Waters Kevin EVP, CFO | Award | 47,462 | $0 |
| Mar 5, 2026 | PUCKETT DAN Director | Award | 5,476 | $0 |
| Mar 5, 2026 | Desai Antal Rohit Director | Purchase | 24,748 | $653.5K |
| Mar 5, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Award | 43,811 | $0 |
| Mar 5, 2026 | Desai Antal Rohit Director | Purchase | 142,498 | $3.63M |
| Mar 5, 2026 | Wood Larry L President, CEO | Award | 127,783 | $0 |
| Feb 19, 2026 | Nouri Alaleh EVP, CLO, CORP. SEC. | Award | 4,872 | $0 |
| Feb 19, 2026 | Waters Kevin EVP, CFO | Award | 3,532 | $0 |
| Sep 2, 2025 | Wood Larry L President, CEO | Award | 182,392 | $0 |
| Aug 14, 2025 | Desai Antal Rohit Director | Option exercise | 26,749 | $35.6K |
| Aug 14, 2025 | Nouri Alaleh EVP, CLO, CORP. SEC. | Option exercise | 11,000 | $49.7K |
| Aug 13, 2025 | MOLL FREDERIC H Director | Purchase | 20,000 | $785.1K |
| Jun 12, 2025 | Desai Antal Rohit Director | Sale 10b5-1 plan | 19,951 | $1.22M |
| Jun 12, 2025 | Desai Antal Rohit Director | Sale 10b5-1 plan | 5,049 | $314.7K |
| Jun 11, 2025 | Desai Antal Rohit Director | Sale 10b5-1 plan | 7,788 | $487.5K |
| Jun 11, 2025 | Desai Antal Rohit Director | Sale 10b5-1 plan | 11,495 | $729.6K |
| Jun 11, 2025 | Desai Antal Rohit Director | Sale 10b5-1 plan | 5,717 | $367.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for PROCEPT BioRobotics Corp
Free account. Everything above stays public.
Write why you follow PROCEPT BioRobotics Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading